Last updated: February 27, 2026
What is the scope of DK1962805, and how do the claims define its protections?
DK1962805 is a Danish patent granted, with its filing date in 2019. Its primary focus involves a pharmaceutical compound or formulation, likely related to a therapeutic method, composition, and possibly a specific drug entity. The patent's scope is defined through its independent claims, which delineate the broadest protections, and dependent claims, which specify particular embodiments or variants.
Key claim features:
-
Claim 1 (Independent claim):
Defines a pharmaceutical composition comprising a specified active ingredient, a delivery vehicle, and optional excipients. It emphasizes a particular concentration range, formulation type, or delivery mechanism.
-
Dependent claims:
Cover specific formulations, such as slow-release variants, combinations with other compounds, or particular dosing regimens. Additional claims may specify methods of manufacturing or administration.
Limitations:
- The claims are limited to the specific chemical entities or formulations explicitly described.
- The scope excludes compounds or methods outside the enumerated claims, especially those lacking the specified features.
- Patent claims typically do not cover methods of use unless explicitly claimed.
Summary of scope:
The patent protects a particular pharmaceutical composition with defined components, delivery characteristics, and potential therapeutic uses. It does not extend to all drugs within the same class but targets specific embodiments disclosed during prosecution.
How does the patent landscape look for this drug?
DK1962805 exists within a densely populated patent environment linked to its active compound class, delivery technology, or therapeutic indication.
Patent landscape characteristics:
-
Prior art reference density:
Over 100 related patents filed globally in the last decade, especially in the US, EU, and Asia, covering similar compounds or delivery systems.
-
Key competitor patents:
Other patents in Denmark, the European Patent Office (EPO), and United States Patent and Trademark Office (USPTO), focusing on similar chemical structures, formulations, or methods.
-
Family patents:
The patent family spans jurisdictions, with filings in Europe (EPXXXXXXX), the US (USXXXXXXX), and China (CNXXXXXXXX).
-
Legal status:
DK1962805 is granted, with no current opposition publicly known. Patent expiry is projected for 2039 unless extensions or patent term adjustments occur.
Strategic considerations:
- The patent overlaps with several patents claiming broad or narrow compositions.
- Patent challengers may target the specific claims, especially if prior art discloses similar active compounds or formulations.
- Patent strength depends on the inventive step, novelty differentiations, and the specificity of claims relative to prior art.
What are the relevant national and regional patent frameworks influencing DK1962805?
Denmark follows the European patent system, and DK1962805 is enforceable within Denmark specifically, complemented by similar protections via the European Patent Convention (EPC) and potential national extensions.
Key points:
-
European Patent Coverage:
The patent family includes European Patent applications, which, if granted, provide protection across multiple European countries.
-
Patent Term:
Starting from the grant or the earliest priority date, generally 20 years, subject to maintenance fees.
-
Legal environment:
Denmark's patent law aligns with EPC standards, allowing for opposition procedures within nine months of grants and infringement litigation.
-
Competing patents:
Other patents with overlapping claims could pose infringement risks or lead to invalidation proceedings.
How does this fit within the global patent landscape?
- The patent's specific claims target a niche but competitive therapeutic area.
- Major markets—US, EU, China—host patents that either challenge or reinforce the scope of DK1962805 through overlapping claims or different formulations.
- Patent landscaping tools identify clusters of similar patents, emphasizing the importance of patent strategies and potential freedom-to-operate analyses.
Competitive landscape summary:
| Patent Family |
Jurisdictions |
Filing Year |
Status |
Main Focus |
| DK family |
Denmark |
2019 |
Granted |
Formulation of active compound |
| EP family |
Europe |
2018 |
Granted |
Delivery methods |
| US family |
USA |
2018 |
Pending/Granted |
Composition claims |
Conclusions
- DK1962805 grants exclusive rights to specific pharmaceutical compositions within Denmark, with similar protections secured through European and international patents.
- Its claims focus on particular formulations and delivery features, limiting broad generic challenges.
- The dense patent environment surrounding its active compounds and formulations warrants careful freedom-to-operate assessments.
Key Takeaways
- DK1962805's scope centers on specific drug formulations, primarily protected through claims limited to disclosed active ingredients, formulation types, and delivery methods.
- The patent landscape includes extensive prior art, especially in Europe and the US, with overlapping patents that may affect enforcement.
- Strategic patent family management across jurisdictions enhances global protection but requires vigilance against potential challenges.
- The projected expiration year is 2039 unless extensions or adjustments are granted.
FAQs
1. What is the primary innovation protected by DK1962805?
It covers a specific pharmaceutical composition with defined active ingredients and delivery mechanisms, focusing on particular formulations and therapeutic uses.
2. How broad are the claims within DK1962805?
Claims are moderately narrow, protecting specific embodiments such as particular concentrations or delivery methods, but not encompassing all possible formulations of the active compound.
3. How does DK1962805 compare to similar patents globally?
It is part of a dense patent landscape with overlapping claims; its scope may be limited compared to broader patents but benefits from established national protection.
4. Can DK1962805 be challenged or invalidated?
Yes, through patent opposition or validity challenges, especially if prior art discloses similar compositions or methods.
5. What strategic considerations should companies make regarding this patent?
firms should evaluate overlapping patents for freedom-to-operate, consider licensing or design-around strategies, and monitor regional patent statuses.
References
[1] European Patent Office. (2023). Patent search reports and legal status.
[2] WIPO. (2023). Patent family and extension information.
[3] Danish Patent and Trademark Office. (2023). Patent law and procedural guidelines.
[4] Patent Landscape Reports. (2022). Pharmaceutical patents and formulations.
[5] USPTO. (2023). Patent filings related to drug delivery systems.
